United States experience and perspectives with trazodone

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Tricyclic antidepressants (TCAs) are traditional treatments for depression.
• TCAs possess a significant side-effect profile and carry risks in overdose.
• Trazodone presents an alternative with a potentially improved safety and efficacy profile.

Purpose of the Study:

• To evaluate the efficacy and safety of trazodone in treating depression.
• To compare trazodone's side-effect profile with that of TCAs.
• To explore new therapeutic applications for trazodone.

Main Methods:

• Comparative efficacy analysis against TCAs.
• Assessment of trazodone's side-effect profile.
• Review of overdose cases involving trazodone.
• Evaluation of long-term safety and efficacy in chronic depression.
• Exploration of trazodone's utility in various psychiatric conditions.

Main Results:

• Trazodone demonstrates comparable efficacy to TCAs in the United States.
• Trazodone exhibits a significantly superior side-effect profile.
• No fatalities have been reported from trazodone overdose alone.
• A starting dose of 150 mg/day, preferably at night, is recommended for depression.
• Preliminary data indicate good safety and efficacy for long-term use (up to 5.5 years) in chronic depression.

Conclusions:

• Trazodone is an effective and safer alternative to TCAs for depression treatment.
• Its favorable side-effect profile and low overdose mortality make it a valuable therapeutic option.
• Trazodone shows promise for treating insomnia, chronic pain, OCD, bulimia nervosa, and psychogeriatric conditions.